Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Express Scripts
Merck
Cipla
Citi
US Department of Justice
Argus Health
Teva
Deloitte

Generated: August 15, 2018

DrugPatentWatch Database Preview

Teva Company Profile

« Back to Dashboard

Summary for Teva
International Patents:789
US Patents:68
Tradenames:471
Ingredients:414
NDAs:712
Patent Litigation for Teva: See patent lawsuits for Teva
PTAB Cases with Teva as petitioner: See PTAB cases with Teva as petitioner

Drugs and US Patents for Teva

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa GRANISETRON HYDROCHLORIDE granisetron hydrochloride INJECTABLE;INJECTION 078392-001 Dec 31, 2007 AP RX No Yes ➤ Try a Free Trial ➤ Try a Free Trial
Teva METOPROLOL TARTRATE metoprolol tartrate TABLET;ORAL 074143-001 Sep 30, 1994 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Teva Womens ADDERALL 15 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 011522-013 Aug 31, 2000 DISCN Yes No 6,384,020*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Teva PROPOXYPHENE COMPOUND 65 aspirin; caffeine; propoxyphene hydrochloride CAPSULE;ORAL 089025-001 Mar 29, 1985 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Teva PENTOXIFYLLINE pentoxifylline TABLET, EXTENDED RELEASE;ORAL 075199-001 Sep 3, 1999 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Teva

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Branded Pharm PROAIR HFA albuterol sulfate AEROSOL, METERED;INHALATION 021457-001 Oct 29, 2004 5,695,743 ➤ Try a Free Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006 6,126,968 ➤ Try a Free Trial
Teva Branded Pharm NASAREL flunisolide SPRAY, METERED;NASAL 020409-001 Mar 8, 1995 4,933,168 ➤ Try a Free Trial
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 6,620,847 ➤ Try a Free Trial
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-002 Jan 27, 2017 6,446,627 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TEVA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-05-17
➤ Subscribe Tablets 0.625 mg ➤ Subscribe 2009-03-02
➤ Subscribe Tablets 0.1 mg/0.02 mg and 0.01 mg ➤ Subscribe 2009-11-16
➤ Subscribe Tablets 0.15 mg/0.03 mg ➤ Subscribe 2004-03-29
➤ Subscribe Extended-release Capsule 15 mg and 30 mg ➤ Subscribe 2008-08-11
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-02-26
➤ Subscribe Tablets 1.25 mg ➤ Subscribe 2008-11-03
➤ Subscribe Tablets 0.3 mg, 0.45 mg and 0.9 mg ➤ Subscribe 2009-03-19
➤ Subscribe Tablets 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg ➤ Subscribe 2013-07-10
➤ Subscribe Tablets 0.15 mg/0.03 mg/0.01 mg ➤ Subscribe 2008-01-22
➤ Subscribe for Injection 3.5 mg/vial ➤ Subscribe 2016-10-26
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-01-29
➤ Subscribe Tablets 5 mg, 10 mg, 20 mg, 30 mg ➤ Subscribe 2009-11-18
Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Try a Free Trial ➤ Try a Free Trial
➤ Try a Free Trial ➤ Try a Free Trial

Non-Orange Book US Patents for Teva

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,989,436 Estrogenic compounds and pharmaceutical formulations comprising the same ➤ Try a Free Trial
9,108,010 Dose counters for inhalers, inhalers and methods of assembly thereof ➤ Try a Free Trial
9,526,850 Dose counters for inhalers, inhalers and methods of assembly thereof ➤ Try a Free Trial
8,338,396 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology ➤ Try a Free Trial
7,842,687 Cephalotaxane derivatives and their processes of preparation and purification ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Teva Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2016 Austria ➤ Try a Free Trial PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON UND DARUNAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON, INSVBESONDERE DARUNAVIR-ETHANOLAT; REGISTRATION NO/DATE: EU/1/14/967 (MITTEILUNG) 20141121
C/GB02/031 United Kingdom ➤ Try a Free Trial PRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319
C/GB03/023 United Kingdom ➤ Try a Free Trial PRODUCT NAME: EZETIMIBE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: DE 54486.00.00 20021017; DE 54488.00.00 20021017; DE 54487.00.00 20021017; DE 54489.00.00 20021017; UK PL 19945/0001 20030404; UK PL 19945/0002 20030404
90035-0 98910359 Sweden ➤ Try a Free Trial PRODUCT NAME: PLAVIX-CLOPIDOGREL; REG. NO/DATE: EU/1/98/069/001 19980715
00133 Netherlands ➤ Try a Free Trial PRODUCT NAME: OLMESARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN DE CARBOXYGROEP GEKOZEN UIT DE VOLGENDE : EEN ALKYLGROEP 1-4 KOOLSTOFATOMEN, EEN BENZYLGROEP, EEN ALKANOYLOXYALKYLGROEP WAARIN HET ALKANOYLDEEL 1-5; NATL. REGISTRATION NO/DATE: RVG 28785-RVG 28787 20030527; FIRST REGISTRATION: DE 502.02.00.00,502.02.01.00, 502.02.02.00 20020813
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Queensland Health
Colorcon
Chinese Patent Office
Baxter
Healthtrust
US Department of Justice
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.